(Q36612290)

15 August 2017

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis (English)

1 reference

15 August 2017

phase II clinical trial

0 references

B Schwartz

14

0 references

Richard Marais

object named as

R Marais

6

0 references

author name string

T Eisen

1

1 reference

15 August 2017

T Ahmad

2

1 reference

15 August 2017

K T Flaherty

3

1 reference

15 August 2017

M Gore

4

1 reference

15 August 2017

S Kaye

5

1 reference

15 August 2017

I Gibbens

7

1 reference

15 August 2017

S Hackett

8

1 reference

15 August 2017

M James

9

1 reference

15 August 2017

L M Schuchter

10

1 reference

15 August 2017

K L Nathanson

11

1 reference

15 August 2017

C Xia

12

1 reference

15 August 2017

R Simantov

13

1 reference

15 August 2017

M Poulin-Costello

15

1 reference

15 August 2017

P J O'Dwyer

16

1 reference

15 August 2017

M J Ratain

17

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

95

1 reference

15 August 2017

5

1 reference

15 August 2017

581-586

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603291

15 August 2017

0 references

cites work

The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360687

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360687

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360687

Metastatic melanoma: is biochemotherapy the future?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360687

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360687

Improving outcomes in advanced malignant melanoma: update on systemic therapy

30 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360687

30 September 2017

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603291

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360687

Clinical significance of BRAF mutations in metastatic melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360687

Guilty as charged: B-RAF is a human oncogene

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360687

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360687

B-RAF is a therapeutic target in melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360687

Mutations of the BRAF gene in human cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360687

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360687

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360687

Differential impact of Raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360687

Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation

20 September 2018

1 reference

12 December 2020

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Suppression of BRAF(V599E) in human melanoma abrogates transformation

1 reference

12 December 2020

BRAF and RAS mutations in human lung cancer and melanoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6603291

1 reference

15 August 2017

1 reference

15 August 2017

1 reference